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myocardial levels of CoQ10 (138.17±39.87 and 56.67±23.08 nmols/g wet weight 
[p--O,O006]), taudne (13.12+4.00 and 7.91±2.81 umoVg wet weight [p--O.0016]), and car- 
nitine (1735.4+798.5 and 1237.6+343.1 nmoVg wet weight [p=0.056 and p=0.028 one 
tailed]). The left ventdcular end diastolic volume (LVEDV) fell by -7.5+21.7 in the supple- 
mented group and increased by 10.0+19.8 in the placebo fed patients (p=0.037). 
Conclusions: Supplementation results in higher myocardial CoQ10, taudne and camitine 
levels and is associated with a reduction in LVEDV in patients with left ventricular dys- 
function prior to revasculadzation. Since the risk of mortality for surgical revasculadzation 
is related to preoperative LVEDV, supplementation could improve outcomes. 
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810-4 Vasopresein Receptor Blockade in Patients With 
Congestive Heart Failure: Results From a Placebo 
Controlled, Randomized Study Comparing the Effects 
of Tolvaptan, Furosemide, and Their Combination 
Jame~ E. UdelsoD, Cesare Orlandi, Torrance O'Brien, Rafael Sequeira, John Ouyang, 
Marvin A. Konstam, Tufts-New England Medical Center, Boston, Massachusetts. 
Background: Increased vasopressin levels contribute to the progression of heart failure 
(HF) to an unknown degree. The presence of diuretics has confounded prior evaluations 
of vasoprassin receptor antagonists (VRA). We investigated the effects of VRA in the 
absence of a diuretic for the first time, with Tolvaptan (OPC-41061, TLV), a novel, non- 
peptide VRA. 
Methods: Pts with HF (NYHA class I1-111, n=83) and signs of congestion (e.g., edema or 
rales) were removed from baseline diuretic therapy and placed on a low-sodium diet (29/ 
day). After a 2-day run-in period, pts were randomized to placebo (n=21), monotherapy 
with TLV 30mg (n=20), monotherapy with furosemide (FURO) 80mg (n=22), or both TLV 
and FURO (n=20) once daily for 7 days. Pts were on standard background therapy and 
not fluid restricted. 
Results: TLV was well tolerated. Table: Changes in body weight and urine volume on last 
study day. An increase in serum Na within the normal range was observed in TLV-treated 
pts (p<0.02 vs placebo; p<0.0f vs FURO). No changes in serum potassium, other lab 
values or BP were observed. Reductions in leg edema, dyspnea, JVP, rales and 
hepatomegaly were also noted in the TLV-traated pts versus placebo. 
Conclusions: In pts with HF and signs of volume overload, TLV monotherapy without 
concomitant loop diuretic therapy reduced body weight and lessened edema when com- 
pared to placebo, without adverse changes in serum electrolytes. These findings support 
a potential therapeutic role of inhibiting vasopressin excess in pts with HF. 
Change from baseline: Placebo TLV FURO TLV+FURO 
Body Wt (kg) +0.72±.2.42 -1.37±1.61" -0.54±1.59 -1.13+1.49" 
Urine output (ml/24hr) +423±786 +2646+1503 *+ +894±853* +2595:P2119 *+ 
* p<0.01 vs baseline 
+ p<0.001 vs FURO 
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810-5 Impact of BEST and COPERNICUS on Overall Estimates 
of Beta-Blocker Survival Benefit in Heart Failure: An 
Updated Mats-Analysis of Randomized Trials 
I~q, yid J. Bradley, Nell R. Powe, Kenneth L. Baughman, Johns Hopkins Hospital, 
Baltimore, Maryland. 
Background: Previous meta-analyses have shown a reduction in mortality among heart 
failure patients treated with beta-blockers. These meta-analyses, however, did not 
include the results of the recently published Beta-Blocker Evaluation of Survival Trial 
(BEST), a large study which did not demonstrate improved survival among heart failure 
patients treated with beta-blockers. In order to assess the impact of BEST on the overall 
estimated efficacy of beta-blockers in symptomatic heart failure, we conducted a mats- 
analysis. We also included the recently published Carvedilol Prospective Randomized 
Cumulative Survival Study (COPERNICUS) in our meta-analysis. 
Methods: Medline and the Cochrane Controlled Trials Register were searched for ran- 
domized controlled trials comparing beta-blockers versus placebo among patients with 
symptomatic left ventricular systolic dysfunction. Twenty-six randomized trials that 
enrolled 15,369 patients were identified, Trials were reviewed independently by two rat- 
ers. Abstracted data included patient exclusion criteria, patient baseline characteristics, 
trial interventions, tdal outcomes, and trial quality. 
Results: Trials were published between 1985 and 2001. Ten trials randomized patients 
to metoprolol, and 9 to carvediloL Baseline ejection fraction ranged from 16% to 34%. 
BEST recorded nearly as many deaths (860) as 24 previously published trials combined 
(1094). Using a random effects model, the pooled odds ratio of death among patients 
treated with beta-blockers versus placebo in 24 trials published before BEST and 
COPERNICUS was 0.65 (95% confidence interval (CI) 0.57 - 0.74). Pooling of mortality 
data from BEST with these previously published 24 trials increased the odds ratio of 
death from 0.65 to 0.73 (95% CI 0.66 - 0.81). tnclusion of mortality data from both BEST 
and COPERNICUS in the mats-analysis yielded an odds ratio of death of 0.71 (95% CI 
0.65 - 0.78). 
Conclusion: Although BEST was a large trial with a negative mortality endpoint, it has 
only modestly diminished the overall estimated survival benefit of beta-blockers in the 
treatment of symptomatic heart failure. 
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Spironolactone Reverses Myocyte Disarray and 
Intereetitial Fibrosis in the Cardiac Troponln T 
Transgenic Mouse Model of Hypertrophic 
Csrdiomyopathy 
Rainikant patal. Shintaro Nemoto, Gilberto DeFraitas, Tripti Halder, Silvia Lutucuta, 
Natalia Tsyboulev, Lorraine Salek, Robert Roberts, Blase Carabello, All J. Marian, Baylor 
College of Medicine, Houston, Texas. 
Hypertrophic cardiomyopathy (HCM), the most common cause of sudden cardiac death 
(SCD) in the young, is caused by mutation in sarcomeric proteins. It is characterized by 
hypertrophy, myocyte disarray, and interstitial fibrosis. We have proposed that hypertro- 
phy, disarray, and fibrosis, major predictors of SCD, are secondary to activation of 
trophic/mitotic factors and intracellular signaling kinases, and thus, are reversible. We 
performed a randomized study to determine the effects of blockade of aldosterone, a 
major mitotic and pro-fibrotic factor, on cardiac phenotypes in the cardiac troponin T- 
glutamine92 (cTnT-Q92) transgenic mice, shown to exhibit significant myocyte disarray 
and interstitial fibrosis. We randomized 26 adult cTnT-Q92 mice to treatment with 
spironolactone (50 mg/kg/d) or placebo (olive oil) for 10 weeks and included 13 non- 
transgenics (non-tg) as controls. We performed M-mode, 2D, and Doppler echocardio- 
graphy prior to and at the completion. There were no significant differences in body 
weight, heart weight, their ratio, male/female ratio, mean age, and heart rates among the 
three groups. Myocyte disarray in non-tg, placebo, and spironolactone groups were 
4.4±2.0, 22.8±9.8, 10.2±3.1% of the myocardium, respectively (p<0.001). Collagen vol- 
ume fraction were (3.4±1.9, 7.2:1:5.9, and 2.8i-0.9%, respectively p=0.001 ). Left ventricu- 
lar end diastolic diameter was smaller (4.3±0.4, 4.1_+0.3, 3.9±0.2, p=0.008) and E/A ratio 
was improved in spironolactone group. Wall thickness and fractional shortening were 
unchanged. Expression levels of activated, but not total, ERK1/2 were increased in the 
placebo and was normalized in spironolectone groups. Levels acticated p38 kinase, 
JNKs, GTP-bound and total Ras, Rac and Rho were unchanged. A duplicate study (n=8 
mice per group) connfirmed the results and showed a 50% reduction in myocyte disarray 
and fibrosis with spironolactone. Thus, myocyte disarray and interstitial fibrosis, the 
pathological hallmarks of HCM and major predictors of SCD, could be reversed with 
aldosterone antagonist, spironolactone. These results in a genetic animal model of HCM, 
beckons clinical studies in human patients with HCM. 
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813-2 Clinical Markers for the Identification of Gene Carriers 
in Naxos Disease Families 
Nikos Protonotarios. Adalena Tsatsopoulou, Ads Anastasakis, Elias Sevdalis, Artamisia 
Theopistou, Antigone Milieu, Angelos Rigopoulos, EvangeUa Karvouni, Chdstodoulos 
Stefanadis, PavIos Toutouzas, Cardiology Dept., University of Athens, Athens, Greece, 
Yiannis Protonotarios Medical Center, Naxos, Greece. 
Background: Naxos disease is a syndrome of arrhythmogenic dght ventdcular cardiomy- 
opethy (ARVC) with autosomal recessive inheritance. The responsible pathogenic gene 
is that of plakoglobin, a constituent of the cardiac and skin cells desmosomes and adher- 
ence junctions. We genotyped patients and members of ARVC families trying to identity 
the clinical characteristics of each genctyped group (homozygous, heterozygous, nor- 
reals). 
Methods: We studied 78 individuals from 12 families (28 patients and 50 family members 
without the stereotype phenotype). Genetic screening involved DNA extraction from 
venous blood, multiplication of a 2Kb area around the PK2157de12 site of the gene 
(where the mutation appears by deletion of 2 bases) by using polymerase chain reaction 
with specifically designed pdmers. Restriction enzyme analysis, using the restriction 
endonucleaseBst01, vedfies the presence or not of the mutation. Clinical assessment 
involved clinical examination, electrocardiography and echocardiography. We performed 
sensitivity-specificity analysis in order to identity specific clinical markers for the gone 
carriers. 
Results: All 28 Naxos ARVC patients were homozygous for the PK2157de12. Among 50 
family members without the stereotype phenotype, 40 were gone carriers (hetarozygous) 
and f0 possessed normal alleles. Curly hair was present in all 28 Naxos ARVc patients, 
in 15 of the 40 gene carriers and in none of the normals (specificity 100%, sensitivity 
37,5% for the heterozygous). Palmoplantar keratoderma was only present in all homozy- 
gous (patients). T wave inversion in lead V3 was present in 20/28 patients, 1/40 het- 
erozygous and 0/10 normals (specificity 100%, sensitivity 2.5% for the tieterozygous). 
Right ventricular outflow tract (RVOT) dilatation (>31ram) was present in 15/28 patients, 
3/40 hetarozygous and 0/10 normals (specificity 100%, sensitivity 53.5% for the het- 
erozygous). 
Conclusion: All Naxos disease patients were homozygous for the plakoglobin gene muta- 
tion. Curly hair, T wave inversion and RVOT enlargement seem to be specific markers for 
identifying the gene carriers among the members of Naxos ARVC families. 
